Protagenic Therapeutics, Inc. (PTIXW)
NASDAQ: PTIXW · Real-Time Price · USD · Warrants
0.1227
-0.0013 (-1.05%)
May 28, 2025, 4:00 PM - Market closed
Company Description
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders.
The company’s lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.
Protagenic Therapeutics, Inc. is headquartered in New York, New York.
Protagenic Therapeutics, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Barrett Evans |
Contact Details
Address: 149 Fifth Avenue, Suite 500 New York, New York 10010 United States | |
| Phone | 212 994 8200 |
| Website | protagenic.com |
Stock Details
| Ticker Symbol | PTIXW |
| Exchange | NASDAQ |
| Stock Type | Warrants |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001022899 |
| CUSIP Number | 74365N111 |
| ISIN Number | US74365N1110 |
Key Executives
| Name | Position |
|---|---|
| Dr. Garo H. Armen Ph.D. | Co-Founder and Executive Chairman of the Board |
| Dr. Alexander Kenneth Arrow C.F.A., M.D. | Chief Financial Officer and Secretary |